1-6 of 6
Brandon Willis
Close
Sort by
Journal Articles

Establishing an AML Ex Vivo Platform to Generate Physiologically Relevant Models

Omid Tavana, Brandon Willis, Siyu Liu, Amanda Christie, Courtney L Andersen, Justine Roderick-Richardson, Amanda Robichaud, Laura Prickett, Corinne Reimer, Lisa Drew
Journal: Blood
Blood (2023) 142 (Supplement 1): 7136.
https://doi.org/10.1182/blood-2023-177856
Published: 2023
Journal Articles

Combination Benefit of Capivasertib and Venetoclax in Preclinical Models of Diffuse Large B-Cell Lymphoma

Brandon Willis, India Neveras, Hannah Dry, Wendan Xu, Yang Li, Kevin Mongeon, Justine Roderick, Alan Rosen, Pavel Klener, Jr., Georg Lenz, Jerome Mettetal, Simon Barry
Journal: Blood
Blood (2021) 138 (Supplement 1): 1870.
https://doi.org/10.1182/blood-2021-153711
Published: 2021
Journal Articles

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Antonio Sacco, Cinzia Federico, Katia Todoerti, Bachisio Ziccheddu, Valentina Palermo, Arianna Giacomini, Cosetta Ravelli, Federica Maccarinelli, Giada Bianchi, Angelo Belotti, Rossella Ribolla, Vanessa Favasuli, Alexey S. Revenko, A. Robert Macleod, Brandon Willis, Hongbo Cai, Joana Hauser, Claire Rooney, Sophie E. Willis, Philip Lloyd Martin, Anna Staniszewska, Helen Ambrose, Lyndsey Hanson, Chiara Cattaneo, Alessandra Tucci, Giuseppe Rossi, Roberto Ronca, Antonino Neri, Stefania Mitola, Niccolò Bolli, Marco Presta, Michele Moschetta, Sarah Ross, Aldo M. Roccaro
Journal: Blood
Blood (2021) 138 (18): 1705–1720.
https://doi.org/10.1182/blood.2020010572
Published: 2021
Includes: Supplemental data
Journal Articles

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Antonio Sacco, RN, Cinzia Federico, PhD, Katia Todoerti, PhD, Bachisio Ziccheddu, PhD, Arianna Giacomini, PhD, Cosetta Ravelli, PhD, Federica Maccarinelli, PhD, Giada Bianchi, MD, Angelo Belotti, Rossella Ribolla, MD, Vanessa Favasuli, Alexey Revenko, PhD, A. Robert MacLeod, PhD, Brandon Willis, PhD, Hongoo Cai, PhD, Joana Hauser, RN, Claire Rooney, PhD, Helen Ambrose, PhD, Anna Staniszewska, PhD, Lyndsey Hanson, PhD, Giuseppe Rossi, Roberto Ronca, PhD, Antonino Neri, MD, Stefania Mitola, PhD, Niccolò Bolli, MD PhD, Marco Presta, PhD, Michele Moschetta, MD PhD, Sarah Ross, PhD, Aldo M. Roccaro, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3104.
https://doi.org/10.1182/blood-2019-124391
Published: 2019
Journal Articles

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Kosinsky Yuri, PhD, Lulu Chu, PhD, Millie Shah, PhD, Karthick Vishwanathan, PhD, Connie Larsson, PhD, Andrew Bloecher, PhD, Brandon Willis, PhD, Hannah Dry, BSc, Kirill Peskov, PhD, Joseph Ware, PhD, Andrew Mortlock, PhD, Gabriel Helmlinger, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5304.
https://doi.org/10.1182/blood-2019-130879
Published: 2019
Journal Articles

Combined Inhibition of mTOR and BTK Signaling Is Required for Optimal Long Term Growth Inhibition in DLBCL Models

Wolfram Brugger, MD, Maureen Hattersley, PhD, Alexandra Bussey, PhD, Corinne Reimer, PhD, Adriana E. Tron, PhD, Anna Staniszewska, PhD, Oona Delpuech, PhD, Larissa Carnevalli, PhD, Cecile M. Krejsa, PhD, Michele Mayo, PhD, Lynne Neveras, PhD, Maryann San Martin, PhD, Abla Rideout, PhD, Theresa Proia, PhD, Brandon Willis, PhD, J. Elizabeth Pease, PhD, Ahmed Hamdy, MD, Sabina C. Cosulich, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4113.
https://doi.org/10.1182/blood.V130.Suppl_1.4113.4113
Published: 2017